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The COVID-19 pandemic is posing challenges in cancer
treatment, with priorities, methods, and timing needing to
be abruptly redefined. Surgery is recognized as the gold
standard treatment for several malignancies, including
prostate cancer (PCa). With all health care systems focused
on virus control, oncologic surgery has been reduced
worldwide.
For how long is it safe for a PCa patient to have his
surgery deferred? As PCa is a heterogeneous disease and
most hospitals worldwide are affected by COVID-19,
prioritization of cases could take advantage of stratification
into risk classes.
High-risk PCa is still diagnosed in almost 27 000 patients
annually in the USA, representing 15% of all cases [1]. By the
end of the last decade, a higher rate of aggressive PCa
patterns (Gleason  4 + 4 and high D’Amico risk) was
detected; the 2012 US Preventive Services Task Force
(USPSTF) recommendation against screening may have
contributed to this occurrence [2].
As part of a multimodal approach, surgery is still the
basis of treatment for high-risk PCa. A recent meta-analysis
by Wang et al [3] highlighted the role of radical
prostatectomy (RP) in this setting: surgery was associated
with higher overall and cancer-specific survival when
compared to radiation therapy (RT). Apart from the
theoretical advantage of RT in eliminating local micro-
metastases, practice shows that a real multimodal approach
is probably applied for patients choosing RP, whereas
patients choosing RT first rarely receive salvage RP.
Recognizing the role of surgery in high-risk PCa, which
are the harms of delayed RP?
The answer to this question can be derived from surgical
experience in the post-2012 USPSTF setting at a referral
center [4]. Cases with aggressive PCa treated with RP are
prone to impaired functional outcomes and a higher rate of
biochemical recurrence at 12 mo, despite no change in
surgical margin status [4]. The latter—representing effective
tumor excision but impaired oncologic follow-up—may
reflect the harm of aggressive PCa, deriving either from
delayed detection or delayed treatment. If a delay would
affect outcomes and RP needs to be carried out in a timely
manner, how can clinicians ensure a safe intervention whilehttps://doi.org/10.1016/j.eururo.2020.04.028
0302-2838/© 2020 Published by Elsevier B.V. on behalf of European Associminimizing the risk of COVID-19 infection during hospitali-
zation?
First, to reduce the burden of surgical interventions and
their impact on patient health, high-risk PCa patients
should be referred to high-volume centers and surgeons,
with the likelihood of a fast discharge and use of an
enhanced recovery after surgery (ERAS) protocol. Further-
more, the decision on whether or not to perform extended
nodal dissection in the current scenario could be debatable
given the lack of certain oncologic benefit and the possible
role of prostate-specific membrane antigen–based positron
emission tomography for preoperative nodal staging
[5]. Currently, pelvic nodal dissection is the major driver
of postoperative complications, carrying a 10% risk of
symptomatic lymphocele [5]. Complications may lead to a
delay in adjuvant treatment and, at worst, leave the patient
prone to postoperative infection due to bacterial or viral
transmission.
Second, safe surgery should be performed in COVID-19–
free facilities, otherwise, according to reports from Wuhan,
postoperative mortality can reach 20% [6]. In addition,
according to the Italian experience, preservation of COVID-
19–free areas within mixed facilities turned out to be
impossible: both caregivers and patients can bring the
infection while asymptomatic, contributing to further
nosocomial spread. Achievement of a real COVID-19–free
facility should rely on a preoperative quarantine period and
laboratory testing to confirm the absence of COVID-19
before entering the institution for both hospital staff and
oncology patients.
As the current pandemic poses unique challenges,
unique replies should be pursued to avoid COVID-19
transmission while ensuring appropriate cancer treatment
and timing during this unpredictable emergency.
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